Research Study

A Phase 3, Randomized, Placebo-controlled, Double-blind, Multicenter, Induction Study to Investigate the Efficacy and Safety of GED-0301 For the Treatment of Subjects With Active Crohn's Disease
Principal Investigator 
Baljinder Salh

Overview

Body Locations and Systems 
Crohn's Disease
ClinicalTrials.gov# 
NCT02596893
Status 
Recruiting
Study Start/End 
Sep 26, 2016 to Dec 29, 2017
Locations 
Diamond Health Care Centre, Vancouver General Hospital
Name/Title 
Jo-Ann E. Ford, Study Coordinator
Phone 
604-875-5705
Email Address 
joann.ford@vch.ca
Purpose of Study 

This study is a clinical research study to see if the investigational medication, GED-0301, is effective in participants with active Crohn’s disease. GED-0301 (mongersen) is a drug taken by mouth that inhibits an immune response in the gut (Smad 7) that causes inflammation (or swelling). 

Eligibility 

Visit ClinicalTrials.gov for more information.

Disclaimer 

Study Coordinators and Research Nurses cannot give medical advice over the phone. Telephone numbers and email addresses are provided for obtaining additional information on specific clinical research trials only. If you have specific questions which require clinical expertise, please call your primary care physician.